Amrize Ltd
AMRZAMRZ operates in the hydraulic cement industry, producing essential construction materials.
As a sector player, its business is fundamentally tied to large-scale infrastructure and building activity levels.
Updated: February 27, 2026, 16:00 EST
Investment Opinion: Should I buy AMRZ Today?
Based on a comprehensive review of AMRZ, the stock presents a conflicted picture with high momentum but concerning fundamentals.
Technical & Valuation Assessment: Technically, AMRZ is exceptionally strong, showing explosive growth and significant alpha. However, its proximity to a 52-week high and overbought condition suggest heightened vulnerability to a pullback. Its valuation appears fair based on forward earnings expectations, but the lack of peer comparison data makes it difficult to confirm if this is attractive relative to the sector.
Fundamental & Risk Concerns: Fundamentally, the picture is weaker. The company faces clear operational headwinds, evidenced by a significant quarterly revenue decline and contracting profit margins. The stock's unusual negative beta adds a layer of complexity, potentially amplifying volatility in a way that contradicts broader market moves.
Recommendation: HOLD.
While the technical momentum is impressive, it appears to be diverging from underlying fundamentals. Investing at this peak carries a high risk of a correction. A more prudent approach would be to wait for a meaningful price pullback or for clearer signs of a fundamental recovery in revenue and profitability before considering a new position. The current risk-reward ratio seems unfavorable for new buyers.
*This is not investment advice, for reference only.*
AMRZ 12-Month Price Forecast
RockFlow Model Forecast: Three Scenarios for 2026
Based on the analysis provided, the 12-month outlook for AMRZ is one of high risk with a neutral-to-cautious stance.
Key catalysts for growth are primarily technical, relying on the continuation of its strong positive momentum to drive the price higher. However, significant potential risks dominate the picture, including the stock's overbought condition near its 52-week high, fundamental weaknesses like declining revenue and profit margins, and its unusual negative beta which could lead to unpredictable volatility. In the absence of a clear analyst target price, the outlook suggests the stock is more likely to experience a pullback or trade sideways as it searches for a fundamental footing, making the current risk-reward ratio unfavorable. The recommendation to wait for a better entry point or signs of operational improvement remains prudent.
Wall Street Consensus
Most Wall Street analysts are optimistic about Amrize Ltd's 12-month outlook, with consensus target around $64.99, indicating expected upside potential.
Bulls vs Bears: AMRZ Investment Factors
Overall, AMRZ has investment potential but also faces challenges. Here are key factors to weigh before investing.
Bullish
- Strong Recent Stock Performance: Stock up 6.7% over the past month, indicating positive momentum.
- Significant Undervaluation: Intrinsic value estimated to be 88% above current share price.
- Powerful Demand Tailwinds: Exposure to infrastructure, energy, data centers, and housing creates structural demand.
- Institutional and Insider Confidence: Recent purchases by PNC Financial and the CFO signal strong belief.
- Solid Fundamentals and Growth: Strong cash flow, 6.6% revenue growth, and a clear path to higher margins.
Bearish
- Recent Price Jump May Limit Upside: The recent share price jump raises questions about timing for new investors.
- Dependence on Economic Cycles: Cement industry is highly cyclical and sensitive to economic downturns.
- High Valuation Multiple: EV/EBITDA of 12.23x may be considered rich, posing a risk if growth slows.
AMRZ Technical Analysis
Of Specialization
Overall Assessment
AMRZ has delivered exceptionally strong performance over recent months, significantly outperforming the broader market.
Short-term Performance
The stock has demonstrated explosive short-term growth, with a substantial 18.38% gain over the past month and an impressive 36.11% surge over the last three months. This performance markedly outpaces the general market, as evidenced by its strong 30.48% relative strength over the same three-month period, indicating significant alpha generation.
Current Position
Trading at $64.16, AMRZ is near the top of its 52-week range ($44.12 - $65.94), sitting just 2.7% below its yearly high. This proximity to the peak, combined with the recent parabolic price ascent, suggests the stock is in an overbought condition and may be vulnerable to a pullback or consolidation, especially given its high negative beta indicating inverse volatility relative to the market.
| Period | AMRZ Return | S&P 500 |
|---|---|---|
| 1m | +21.2% | -1.4% |
| 3m | +35.0% | +4.1% |
| 6m | +31.8% | +7.5% |
| 1y | +25.0% | +15.4% |
| ytd | +17.2% | +0.4% |
AMRZ Fundamental Analysis
Revenue & Profitability: AMRZ experienced a significant quarter-over-quarter revenue decline from $3.68 billion to $2.84 billion in Q4 2025. This decline translated into weaker profitability, with the net income ratio falling from 14.8% to 10.5%, driven by a substantial drop in operating income. The contraction in both top-line performance and profit margins suggests near-term operational headwinds.
Financial Health: The company maintains a manageable interest expense relative to operating income, with coverage remaining stable at approximately 5.7x in Q4. While the provided data lacks a full balance sheet to calculate a precise debt ratio, the consistent EBITDA generation, though reduced in Q4, supports ongoing debt servicing capabilities. Further analysis of long-term debt levels is required for a complete health assessment.
Operational Efficiency: Operating efficiency softened in the latest quarter, evidenced by the operating income ratio declining from 21.1% to 17.0%. The sequential drop in revenue also implies a potential slowdown in asset turnover. Without historical balance sheet data, a precise Return on Equity (ROE) cannot be calculated, but the lower net income suggests reduced returns on shareholder capital for the period.
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
RockFlow Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Try Now & Get Tesla Stock RewardValuation Analysis: Is AMRZ Overvalued?
Based on the available metrics, AMRZ appears modestly valued relative to its current earnings. The trailing PE ratio of 29.7 is elevated, suggesting a premium for recent performance, but the forward PE of 20.2 indicates expected earnings growth that provides a more reasonable valuation outlook. The moderate EV/EBITDA of 13.9 and PB ratio of 2.7 generally support this assessment of a fair, though not deeply discounted, valuation level.
A comprehensive peer comparison cannot be accurately completed as industry average data is unavailable. Without benchmarks for standard valuation metrics like PE, PB, or EV/EBITDA relative to its sector, it is impossible to determine if AMRZ trades at a premium or discount to comparable companies. This analysis would require the relevant industry data to place these absolute valuation figures into proper context.
Investment Risk Disclosure
Volatility Risk Analysis: AMRZ exhibits an unusual risk profile with a negative Beta of -1.34, indicating it has historically moved inversely to the broader market. This could amplify portfolio volatility during market rallies. The relatively modest 1-year maximum drawdown of -15.59% suggests moderate historical downside risk, though the negative Beta implies this may not be representative during strong bull markets.
Other Risks Analysis: The absence of reported short interest implies no significant speculative pressure against the stock, potentially reducing near-term downside risk from short squeezes. However, the lack of short interest data could also indicate extremely low liquidity or minimal market participation, which may present significant execution risks and price inefficiencies for investors.
FAQs
Bullish - AMRZ appears fundamentally attractive despite near-term caution flags. Key supports include strong structural demand tailwinds, undervaluation potential (intrinsic value estimates well above current price), and unanimous analyst buy ratings. However, the stock is overbought technically with softening quarterly fundamentals, making it more suitable for long-term growth investors who can tolerate cyclical volatility and potential short-term consolidation.
Based on the provided data, AMRZ stock appears modestly overvalued. Key metrics like its trailing PE of 29.7 and PS ratio of 2.97 are elevated without the context of industry averages for comparison. This valuation seems to rely on future growth expectations, as indicated by the lower forward PE of 20.2. However, this optimism is difficult to justify given the company's significant Q4 revenue decline and contracting profit margins, which signal near-term operational headwinds rather than strong growth.
Of course. As a risk management analyst, here is an objective assessment of the key risks of holding AMRZ stock, based on the provided information.
Key Risks of Holding AMRZ
1. Market Correlation Risk: The stock's strongly negative beta (-1.34) indicates it has historically moved inversely to the broader market, creating a high risk of underperformance or significant losses during sustained market rallies. 2. Operational & Profitability Risk: The company is facing clear operational headwinds, evidenced by a significant quarter-over-quarter revenue decline and a sharp contraction in both operating and net profit margins. 3. Technical Price Risk: After a parabolic price ascent, the stock is trading near its 52-week high and appears overbought, creating a pronounced vulnerability to a sharp technical pullback or consolidation. 4. Liquidity & Execution Risk: The absence of reported short interest, while reducing squeeze risk, may indicate extremely low trading liquidity, which can lead to significant price inefficiencies and difficulty executing orders at predictable prices.
Of course. Here is the forecast for AMRZ stock through 2026, based on a professional assessment of the provided data.
AMRZ Stock Forecast through 2026
1. Target Price Range: * Base Case (2026): $55 - $65. This reflects a period of consolidation and potential downside as the market prices in operational headwinds and searches for a fundamental catalyst. * Bull Case (2026): $75 - $85. This scenario is contingent on a successful reversal of the revenue decline and significant improvement in profit margins, likely driven by new product cycles or market share gains.
2. Key Growth Drivers: * Operational Turnaround: The primary driver is reversing the recent quarter-over-quarter revenue decline and restoring operating margins above 20%. * Market Sentiment & Momentum: Despite fundamental weaknesses, a continuation of its positive technical momentum could propel the stock higher, though this is considered a higher-risk catalyst. * Industry Tailwinds: Outperformance will depend on the company capitalizing on specific growth opportunities within its sector that are not yet evident from the data.
3. Main Assumptions: * The Q4 2025 revenue and margin contraction is not an isolated event but indicates sustained near-term headwinds. * Management executes a credible strategy to reignite growth and improve efficiency by late 2026. * Macroeconomic conditions remain stable, not exacerbating the company's current challenges.
4. Uncertainty of the Forecast: This forecast carries high uncertainty due to the conflicting signals between weak fundamentals (declining revenue, margins) and strong technicals (price near 52-week highs). The stock's negative beta adds a layer of unpredictability, making its reaction to broader market movements difficult to gauge. The absence of clear analyst targets further underscores the lack of consensus.